US 12,162,838 · Application 18/136,016 · Granted Dec 10, 2024
US 12,162,838
Human plasma kallikrein inhibitors
Estimated expiration
March 9, 2035
8y 134d remaining
Earliest effective filing
Mar 9, 2015
+ 20 years
Mar 9, 2035
PTA +0d
Mar 9, 2035
TD cap (US 11,192,861)
Mar 9, 2035
Final
Mar 9, 2035
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).
Calculation details
Base term
- Filing date
- April 18, 2023
- Earliest effective filing
- March 9, 2015
- Issue date
- December 10, 2024
- PTA
- 0 days
- Base expiry (before PTA)
- March 9, 2035
March 9, 2015 + 20 years = March 9, 2035
- Continuation of application 17/522,065, filed Nov 9, 2021, issued as US 11,685,721
- Continuation of application 16/828,755, filed Mar 24, 2020, issued as US 11,192,861
- Continuation of application 16/009,943, filed Jun 15, 2018, issued as US 10,633,345
- Divisional of application 15/123,059, filed Sep 1, 2016, issued as US 10,125,102
- National stage entry of application PCTUS2015019535, filed Mar 9, 2015
- National stage entry of application PCTUS2015019535, filed Mar 9, 2015
- Divisional of application 15/123,059, filed Sep 1, 2016, issued as US 10,125,102
- National stage entry of application PCTUS2015019535, filed Mar 9, 2015
- Continuation of application 16/009,943, filed Jun 15, 2018, issued as US 10,633,345
- Divisional of application 15/123,059, filed Sep 1, 2016, issued as US 10,125,102
- National stage entry of application PCTUS2015019535, filed Mar 9, 2015
- Continuation of application 16/828,755, filed Mar 24, 2020, issued as US 11,192,861
- Continuation of application 16/009,943, filed Jun 15, 2018, issued as US 10,633,345
- Divisional of application 15/123,059, filed Sep 1, 2016, issued as US 10,125,102
- National stage entry of application PCTUS2015019535, filed Mar 9, 2015
- PRO61/949,808 — Provisional — not used for base term
- PRO61/981,515 — Provisional — not used for base term
- PRO61/949,808 — Provisional — not used for base term
- PRO61/981,515 — Provisional — not used for base term
- PRO61/981,515 — Provisional — not used for base term
- PRO61/949,808 — Provisional — not used for base term
- PRO61/981,515 — Provisional — not used for base term
- PRO61/949,808 — Provisional — not used for base term
- PRO61/981,515 — Provisional — not used for base term
- PRO61/949,808 — Provisional — not used for base term
- PRO61/981,515 — Provisional — not used for base term
- PRO61/949,808 — Provisional — not used for base term
Terminal disclaimers
TD caps expiration to March 9, 2035 (earliest expiring referenced patent: US 11,192,861)
US 10,633,345· Application 16/009,943Capping patent
Human plasma kallikrein inhibitors
- Filing date
- Jun 15, 2018
- Earliest effective filing
- Mar 9, 2015
- Issue date
- Apr 28, 2020
- PTA
- +22 days
- Calculated expiration
- Mar 31, 2035
Divisional of 15/123,059, filed Sep 1, 2016, issued as US 10,125,102
National stage entry of PCTUS2015019535, filed Mar 9, 2015
National stage entry of PCTUS2015019535, filed Mar 9, 2015
Mar 9, 2015 + 20y + 22d PTA = Mar 31, 2035
US 11,192,861· Application 16/828,755Capping patent
Human plasma kallikrein inhibitors
- Filing date
- Mar 24, 2020
- Earliest effective filing
- Mar 9, 2015
- Issue date
- Dec 7, 2021
- PTA
- 0 days
- Calculated expiration
- Mar 9, 2035
Continuation of 16/009,943, filed Jun 15, 2018, issued as US 10,633,345
Divisional of 15/123,059, filed Sep 1, 2016, issued as US 10,125,102
National stage entry of PCTUS2015019535, filed Mar 9, 2015
National stage entry of PCTUS2015019535, filed Mar 9, 2015
Divisional of 15/123,059, filed Sep 1, 2016, issued as US 10,125,102
National stage entry of PCTUS2015019535, filed Mar 9, 2015
Mar 9, 2015 + 20y = Mar 9, 2035
US 11,685,721· Application 17/522,065
Human plasma kallikrein inhibitors
- Filing date
- Nov 9, 2021
- Earliest effective filing
- Mar 9, 2015
- Issue date
- Jun 27, 2023
- PTA
- 0 days
- Calculated expiration
- Mar 9, 2035
Continuation of 16/828,755, filed Mar 24, 2020, issued as US 11,192,861
Continuation of 16/009,943, filed Jun 15, 2018, issued as US 10,633,345
Divisional of 15/123,059, filed Sep 1, 2016, issued as US 10,125,102
National stage entry of PCTUS2015019535, filed Mar 9, 2015
National stage entry of PCTUS2015019535, filed Mar 9, 2015
Divisional of 15/123,059, filed Sep 1, 2016, issued as US 10,125,102
National stage entry of PCTUS2015019535, filed Mar 9, 2015
Continuation of 16/009,943, filed Jun 15, 2018, issued as US 10,633,345
Divisional of 15/123,059, filed Sep 1, 2016, issued as US 10,125,102
National stage entry of PCTUS2015019535, filed Mar 9, 2015
Mar 9, 2015 + 20y = Mar 9, 2035
US 9,576,408· Application 14/810,662
Battery powered trainable remote garage door opener module
- Filing date
- Jul 28, 2015
- Earliest effective filing
- Jul 28, 2015
- Issue date
- Feb 21, 2017
- PTA
- 0 days
- Calculated expiration
- Jul 28, 2035
Jul 28, 2015 + 20y = Jul 28, 2035
US 12,162,838· Application 18/136,016(from application 18/136,016)
Human plasma kallikrein inhibitors
- Filing date
- Apr 18, 2023
- Earliest effective filing
- Mar 9, 2015
- Issue date
- Dec 10, 2024
- PTA
- 0 days
- Calculated expiration
- Mar 9, 2035
Continuation of 17/522,065, filed Nov 9, 2021, issued as US 11,685,721
Continuation of 16/828,755, filed Mar 24, 2020, issued as US 11,192,861
Continuation of 16/009,943, filed Jun 15, 2018, issued as US 10,633,345
Divisional of 15/123,059, filed Sep 1, 2016, issued as US 10,125,102
National stage entry of PCTUS2015019535, filed Mar 9, 2015
National stage entry of PCTUS2015019535, filed Mar 9, 2015
Divisional of 15/123,059, filed Sep 1, 2016, issued as US 10,125,102
National stage entry of PCTUS2015019535, filed Mar 9, 2015
Continuation of 16/009,943, filed Jun 15, 2018, issued as US 10,633,345
Divisional of 15/123,059, filed Sep 1, 2016, issued as US 10,125,102
National stage entry of PCTUS2015019535, filed Mar 9, 2015
Continuation of 16/828,755, filed Mar 24, 2020, issued as US 11,192,861
Continuation of 16/009,943, filed Jun 15, 2018, issued as US 10,633,345
Divisional of 15/123,059, filed Sep 1, 2016, issued as US 10,125,102
National stage entry of PCTUS2015019535, filed Mar 9, 2015
Mar 9, 2015 + 20y = Mar 9, 2035
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 18/136,016 · US 12,162,838
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 12,162,838: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One new public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US12162838Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.